Drug Profile
Pegfilgrastim biosimilar - Amega Biotech
Alternative Names: Peg-filgrastim biosimilar - Amega Biotech; Peg-Neutropine; Recombinant pegfilgrastim - Amega BiotechLatest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator Amega Biotech
- Developer Amega Biotech; Megalabs
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 25 Apr 2022 Megalabs initiates enrolment in a phase I pharmacokinetic trial in healthy volunteers in Brazil (NCT04873765)
- 18 Mar 2022 Phase-I clinical trials in Neutropenia (In volunteers) in Brazil (SC) (NCT04873765)
- 05 May 2021 Megalabs plans a phase I trial in Neutropenia (In volunteers) (SC, Injection) in June 2021 (NCT04873765)